Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • COVID-19
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • COVID-19
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Treatment and Outcomes

Campath 1-H (Anti-CD52) for Refractory Vasculitis: Retrospective Cambridge Experience 1989–1999

DRW Jayne,
Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-129;
DRW Jayne
Addenbrooke’s Hospital, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 69 no. 4 suppl 2 SII-129

Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869

Copyright & Usage 
Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 69 (4 suppl 2)
Cleveland Clinic Journal of Medicine
Vol. 69, Issue 4 suppl 2
1 Apr 2002
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Campath 1-H (Anti-CD52) for Refractory Vasculitis: Retrospective Cambridge Experience 1989–1999
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Campath 1-H (Anti-CD52) for Refractory Vasculitis: Retrospective Cambridge Experience 1989–1999
DRW Jayne
Cleveland Clinic Journal of Medicine Apr 2002, 69 (4 suppl 2) SII-129;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Campath 1-H (Anti-CD52) for Refractory Vasculitis: Retrospective Cambridge Experience 1989–1999
DRW Jayne
Cleveland Clinic Journal of Medicine Apr 2002, 69 (4 suppl 2) SII-129;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Treatment and Outcomes

  • Treatment of giant-cell arteritis: where we have been and why we must move on
  • Henoch-Schönlein purpura (treatment and outcome)
  • Randomized Trial of Cyclophosphamide Versus Methotrexate for Induction of Remission in “Non-Renal” Anca-Associated Vasculitis
Show more Treatment and Outcomes

Plenary Session Abstract

  • Sequential Epitope Mapping of the Myeloperoxidase Antigen
  • Henoch-Schönlein Purpura and Cutaneous Leukocy-Toclastic Angiitis Exhibit Different HLA-DRB1 Associations
  • Randomized Trial of Cyclophosphamide Versus Methotrexate for Induction of Remission in “Non-Renal” Anca-Associated Vasculitis
Show more Plenary Session Abstract

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2022 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire